AMPE : Summary for Ampio Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets close in 2 hrs 51 mins

Ampio Pharmaceuticals, Inc. (AMPE)

NYSE MKT - NYSE MKT Real Time Price. Currency in USD
Add to watchlist
0.84+0.02 (+2.88%)
As of 12:58PM EST. Market open.
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close0.82
Bid0.00 x
Ask0.00 x
Day's Range0.82 - 0.85
52 Week Range0.59 - 4.32
Avg. Volume409,090
Market Cap48.24M
PE Ratio (TTM)-1.71
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire5 hours ago

    Ampio Hosting Conference Call Tuesday, March 7, 4:30pm EST

    ENGLEWOOD, Colo., March 1, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT:  AMPE) will host an investor conference call Tuesday, March 7 th at 4:30 pm EST. Participants are invited to dial-in ...

  • PR Newswire2 days ago

    Ampio Receives Guidance from the FDA and Proposes a Path for Approval for Single-Injection Ampion™ for the Treatment of Pain Due to Severe Osteoarthritis of the Knee

    ENGLEWOOD, Colo., Feb. 27, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced that the Office of Tissue and Advanced Therapies (OTAT), a branch of the Center for Biologics Evaluation and Research (CBER) of the FDA, has recently provided additional guidance for the path to approval of Ampion™ as a treatment for pain due to severe Osteoarthritis of the knee (OAK). The FDA acknowledged an unmet medical need in patients with pain due to severe OAK, graded as Kellgren-Lawrence Grade 4 (KL 4), where there are currently no FDA approved treatments for this population.

  • PR Newswire7 months ago

    Ampio Updates Regulatory Status of AMPION™

    ENGLEWOOD, Colo., Aug. 3, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today that it has filed a meeting request and Briefing Document with the FDA to seek guidance on the filing of the company's Biological License Application (BLA) for Ampion™ to treat patients suffering from pain caused by severe Osteoarthritis (OA) of the knee. In the second quarter of this year, Ampio submitted their Chemistry Manufacturing and Controls (CMC) documents for Ampion™ with the FDA, and requested the Agency provide any related guidance. Ampio also announced that the STRUT Study that treated pain due to OA of the knee with multiple injections of Ampion™, authored by Dr. John Schwappach, the trials Principal Investigator, was accepted for publication in the peer-reviewed journal "Orthopedics."  As soon as the journal is in print, we will post the article on Ampio's website.